CCL21-DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer

Sherven Sharma; Pournima Kadam; Ram P Singh; Michael Davoodi; Maie St John; Jay M Lee; Sherven Sharma; Pournima Kadam; Ram P Singh; Michael Davoodi; Maie St John; Jay M Lee

doi:10.3934/medsci.2021022

AIMS Medical Science

2021, Volume 8, Issue 4: 269-275. doi: 10.3934/medsci.2021022

Previous Article Next Article

Review Topical Sections

CCL21-DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer

1.
Department of Medicine; UCLA Lung Cancer Research Program; David Geffen School of Medicine at UCLA; Los Angeles, CA USA
2.
Molecular Gene Medicine Laboratory; Veterans Affairs Greater Los Angeles Healthcare System; Los Angeles, CA USA
3.
Jonsson Comprehensive Cancer Center; David Geffen School of Medicine at UCLA; Los Angeles, CA USA

Received: 27 April 2021 Accepted: 23 September 2021 Published: 12 October 2021

Targeting inhibitory immune checkpoint molecules has highlighted the need to find approaches enabling the induction and activation of an immune response against cancer. Therapeutic vaccination, which can induce a specific immune response against tumor antigens, is an important approach to consider. Although this approach has shown low clinical efficacy when combined with other treatment modalities, therapeutic cancer vaccines will have a better outcome when combined with immune checkpoint blockade therapy with potential for cancer free survival. In this review, we will discuss the results of our two recent publications in preclinical lung cancer models. Our studies reveal that anti-PD-1 administered in combination with CCL21-DC tumor antigen therapeutic vaccines eradicate lung cancer. The results of these studies highlight the importance of combination therapy of immune checkpoint blockade and therapeutic cancer vaccines for lung cancer patients.
- lung cancer,
- PD-1,
- immune checkpoint,
- CCL21,
- dendritic cells (DC),
- T cells,
- immune therapy,
- tumor peptide antigens (Ag),
- tumor lysate Ag,
- tumor microenvironment (TME)
Citation: Sherven Sharma, Pournima Kadam, Ram P Singh, Michael Davoodi, Maie St John, Jay M Lee. CCL21-DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer[J]. AIMS Medical Science, 2021, 8(4): 269-275. doi: 10.3934/medsci.2021022

Related Papers:

Abstract

Targeting inhibitory immune checkpoint molecules has highlighted the need to find approaches enabling the induction and activation of an immune response against cancer. Therapeutic vaccination, which can induce a specific immune response against tumor antigens, is an important approach to consider. Although this approach has shown low clinical efficacy when combined with other treatment modalities, therapeutic cancer vaccines will have a better outcome when combined with immune checkpoint blockade therapy with potential for cancer free survival. In this review, we will discuss the results of our two recent publications in preclinical lung cancer models. Our studies reveal that anti-PD-1 administered in combination with CCL21-DC tumor antigen therapeutic vaccines eradicate lung cancer. The results of these studies highlight the importance of combination therapy of immune checkpoint blockade and therapeutic cancer vaccines for lung cancer patients.

Acknowledgments

Financial disclosure: This work was supported by VA Merit Award I01BX003171.

Ethical disclosure

All animal work was conducted in accord with the Veterans Affairs Institutional Animal care and Use Committee guidelines: id D16-00002. The Animal Care and Use Committee review board approved all the studies involving animals.

Conflict of interest

All the authors declare that there are not biomedical financial interests or potential conflicts of interest in writing this manuscript.

References

[1]	Fitzmaurice C, Abate D, Abbasi N, et al. (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 5: 1749-1768. doi: 10.1001/jamaoncol.2019.2996
[2]	Nerviani A, Pitzalis C (2018) Role of chemokines in ectopic lymphoid structures formation in autoimmunity and cancer. J Leukoc Biol 104: 333-341. doi: 10.1002/JLB.3MR0218-062R
[3]	Colbeck EJ, Ager A, Gallimore A, et al. (2017) Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front Immunol 8: 1830. doi: 10.3389/fimmu.2017.01830
[4]	Lee JM, Lee MH, Garon E, et al. (2017) Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin Cancer Res 23: 4556-4568. doi: 10.1158/1078-0432.CCR-16-2821
[5]	Ancevski Hunter K, Socinski MA, Villaruz LC (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22: 1-10. doi: 10.1007/s40291-017-0308-6
[6]	Brahmer JR, Govindan R, Anders RA, et al. (2018) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 6: 75. doi: 10.1186/s40425-018-0382-2
[7]	Diskin B, Adam S, Cassini MF, et al. (2020) PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol 21: 442-454. doi: 10.1038/s41590-020-0620-x
[8]	Freeman GJ, Long AJ, Iwai Y, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034. doi: 10.1084/jem.192.7.1027
[9]	Cyster JG (1999) Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189: 447-450. doi: 10.1084/jem.189.3.447
[10]	Kadam P, Singh RP, Davoodi M, et al. (2020) Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine. Vaccines (Basel) 8: 655. doi: 10.3390/vaccines8040655
[11]	Kadam P, Sharma S (2020) PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer. Vaccines (Basel) 8: 317. doi: 10.3390/vaccines8020317
[12]	Kadam P, Singh R, Davoodi M, et al. (2020) Immune checkpoint blockade enhances immune activity of therapeutic lung cancer vaccine. Vaccines (Basel) 8: 655. doi: 10.3390/vaccines8040655
[13]	Hollingsworth RE, Jansen K (2019) Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 4: 7. doi: 10.1038/s41541-019-0103-y
[14]	Mougel A, Terme M, Tanchot C (2019) Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front Immunol 10: 467. doi: 10.3389/fimmu.2019.00467
[15]	Jou J, Harrington KJ, Zocca MB, et al. (2021) The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification. Clin Cancer Res 27: 689-703. doi: 10.1158/1078-0432.CCR-20-0245
[16]	Del Re M, Rofi E, Restante G, et al. (2018) Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 9: 6630-6643. doi: 10.18632/oncotarget.23553
[17]	Varghese AM, Sima CS, Chaft JE, et al. (2013) Lungs don't forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J Thorac Oncol 8: 123-125. doi: 10.1097/JTO.0b013e31827914ea
[18]	Riely GJ, Kris MG, Rosenbaum D, et al. (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731-5734. doi: 10.1158/1078-0432.CCR-08-0646
[19]	Subramanian J, Govindan R (2007) Lung cancer in never smokers: a review. J Clin Oncol 25: 561-570. doi: 10.1200/JCO.2006.06.8015
[20]	Du Y, Cui X, Sidorenkov G, et al. (2020) Lung cancer occurrence attributable to passive smoking among never smokers in China: a systematic review and meta-analysis. Transl Lung Cancer Res 9: 204-217. doi: 10.21037/tlcr.2020.02.11
[21]	Couraud S, Zalcman G, Milleron B, et al. (2012) Lung cancer in never smokers—a review. Eur J Cancer 48: 1299-1311. doi: 10.1016/j.ejca.2012.03.007
[22]	Cheng ES, Egger S, Hughes S, et al. (2021) Systematic review and meta-analysis of residential radon and lung cancer in never-smokers. Eur Respir Rev 30. doi: 10.1183/16000617.0230-2020
[23]	Alexandrov LB, Ju YS, Haase K, et al. (2016) Mutational signatures associated with tobacco smoking in human cancer. Science 354: 618-622. doi: 10.1126/science.aag0299
[24]	Blackford A, Parmigiani G, Kensler TW, et al. (2009) Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 69: 3681-3688. doi: 10.1158/0008-5472.CAN-09-0015
[25]	Hodi FS, O'day SJ, Mcdermott DF, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723. doi: 10.1056/NEJMoa1003466
[26]	Topalian SL, Hodi FS, Brahmer JR, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454. doi: 10.1056/NEJMoa1200690
[27]	Robert C, Thomas L, Bondarenko I, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526. doi: 10.1056/NEJMoa1104621
[28]	Alexander M, Galeas J, Cheng H (2018) Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell? J Thorac Dis 10: S3994-S3998. doi: 10.21037/jtd.2018.09.35
[29]	Willis C, Fiander M, Tran D, et al. (2019) Tumor mutational burden in lung cancer: a systematic literature review. Oncotarget 10: 6604-6622. doi: 10.18632/oncotarget.27287
[30]	Westcott PM, Halliwill KD, To MD, et al. (2015) The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517: 489-492. doi: 10.1038/nature13898
[31]	Conway JR, Kofman E, Mo SS, et al. (2018) Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med 10: 93. doi: 10.1186/s13073-018-0605-7
[32]	Zappasodi R, Merghoub T, Wolchok JD (2018) Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33: 581-598. doi: 10.1016/j.ccell.2018.03.005
[33]	Simon S, Labarriere N (2017) PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7: e1364828. doi: 10.1080/2162402X.2017.1364828
[34]	Tumeh PC, Harview CL, Yearley JH, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571. doi: 10.1038/nature13954

Reader Comments

Your name:*

Email:*
© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)